Related to Celera Gets CE Mark for KIF6 Genetic Test for Coronary Heart Disease Risk

• BMS’ Sprycel Cleared in EU for Newly Diagnosed Ph+ CML Therapy
  
• Novartis Withdraws U.S. and EU sNDAs for Zometa in Breast Cancer
  
• FDA and EMA Take Steps to Restrict Avastin Use in Breast Cancer
  
• Cepheid Launches CE-Marked Xpert Flu IVD Test in Europe
  
• EC Clears Novartis’ Lucentis for Diabetic Macular Edema
  
• CHMP Upholds Previous Negative Opinion on Merck KGaA’s MS Therapy
  
• Biogen Idec’s Fampyra for MS Fails to Win CHMP Support in Europe
  
• Novartis Wins Positive Recommendation for Its MS Drug from CHMP
  
• EMA Road Map Aims to Stimulate Drug Development for Unmet Medical Needs and Rare and Neglected Diseases
  
• AmoyDx Gains CE Mark for EGFR, KRAS, and BRAF Tests
  
• Pfizer Wins EMA Approval to Market Dupuytren Contracture Therapy
  
• Baxter’s Vero Cell Seasonal Flu Vaccine Preflucel Approved in 13 European Countries
  
• Gamma Partners with Health Diagnostic Lab to Develop Risk Assay for Heart Attack and Stroke
  
• EC Approves InterMune’s Esbriet for the Treatment of Idiopathic Pulmonary Fibrosis
  
• EC Approves BMS and AstraZeneca’s Type 2 Diabetes Therapy for Renally Impaired Patients
  
• EC Approves Janssen’s Extended-Release Injectable Schizophrenia Drug Xeplion
  
• Quest to Buy Celera for $344M Net Through $8 Per Share Cash Deal
  
• EU Sanctions Novartis’ Multiple Sclerosis Drug Gilenya
  
• Amgen to Appeal EMA’s Negative Opinion on Vectibix Combination with Chemotherapy
  
• Cepheid Eyes Two-Week Shipping for Xpert Flu Diagnostic in the U.S.